



Compound Toolbox

Early access to
Oncology compounds
covering key cancer
pathways

AstraZeneca Oncology
Innovative Medicines





Outline

Introduction to compound toolbox

Content of the toolbox

Access to the compounds

Contact information

Compound Toolbox allows early access to AZ Oncology portfolio compounds for pre-clinical research

- ❖ **Toolbox compounds modulate cancer-relevant pathways, including Apoptosis, Cell Cycle, DNA repair, Angiogenesis, RTK pathways**
- ❖ **Opportunity to conduct high quality research to investigate cancer signaling pathways, evaluate novel combinations , develop novel cancer models, test new indications and discover novel biology**
- ❖ **Streamlined approval process and compound dispatch process in place**
- ❖ **Exciting opportunity to build productive pre-clinical collaborations with AZ oncology scientists**
- ❖ **Potential to develop new clinical opportunities**

Cell Cycle Control

DNA Repair

Olaparib

AZD5363



AZD6738

AZD7762


AZD1152

AZD4877


R&D | Innovative Medicines



Apoptosis Pathway




Angiogenesis Pathways



* Inhibitors available

JAK/STAT Signaling Pathway



AZ Compound Toolbox Categories



AZ Tool compounds

- Requires MTA
- Requires research proposal



AZ Current clinical

- Requires MTA
- Requires research proposal
- Proposal requires project team approval

AZ Clinical candidates

Compound	Target(s)
Selumetinib	MEK
Olaparib	PARP
Vandetanib	VEGFR, EGFR, RET
AZD4547	FGFR
AZD1208	Pim1, 2, and 3
AZD9291	EGFRmutant
AZD4320	BCL2/BCLxl
AZD5363	AKT
AZD6738	ATR
AZD2014	TORC1/2
AZD8186	PI3K beta
AZD1152	Aurora kinase
AZD1775	Wee1
AZD9150	STAT3 (antisense)

AZ Tool Compounds

Compound	Target(s)
AZD6495	CSF1R
AZD4877	EG5
AZ12609721	Ephrin receptor B4
AZ12253801	IGFR
AZD1332	TRK
AZD8542	SMO
AZD7762	CHK
AZD5582	IAP
AZD0530	Src kinase
AZ12419304	BRAF
AZ12823138	Mutant BRAF

Compound	Target(s)
AZD1480	JAK2 kinase
AZD3463	AnLK
AZD3514	Androgen Receptor
AZD8931	Pan-ERBB
AZD8055	TORC1/2

Streamlined process to obtain Toolbox compounds

- ❖ In vitro and in vivo activity of compounds are available upon request (CDA may be required)
- ❖ Submit research proposal to an AZ Oncology External Science Manager that outlines hypothesis and experimental plan using AZ template available
- ❖ Proposal will be reviewed within 4 weeks from submission
- ❖ Appropriate MTA will be supplied for signature after approval
- ❖ Compound will be dispatched within 1 week of final signed MTA
- ❖ 6 month check-in of progress
- ❖ Send resulting manuscripts 30 days prior to submission



Contact information

[AZ-Compound-
Toolbox@astrazeneca.com](mailto:AZ-Compound-Toolbox@astrazeneca.com)